Login to Your Account



Pharma: Other News To Note


Tuesday, July 23, 2013

• Baxter International Inc., of Deerfield, Ill., said the European Medicines Agency authorized an update to the summary of product characteristics (smPC) for Advate [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method, or octocog alfa)] to include findings of its Phase IV prophylaxis study, which compared standard and pharmacokinetic (PK)-guided prophylaxis dosing regimens to on-demand treatment with Advate.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription